The antiinflammatory activity of intravenous immunoglobulin (IVIG) is dependent on the presence of sialic acid in the core IgG fragment crystallizable domain (Fc) glycan, resulting in increased conformational flexibility of the C2 domain with corresponding modulation of Fc receptor (FcR) binding specificity from type I to type II receptors. Sialylated IgG Fc (sFc) increases the activation threshold of innate effector cells to immune complexes by stimulating the up-regulation of the inhibitory receptor FcγRIIB. We have found that the structural alterations induced by sialylation can be mimicked by specific amino acid modifications to the C2 domain. An IgG Fc variant with a point mutation at position 241 (F241A) exhibits anti-inflammatory activity even in the absence of sialylation. F241A and sFc protect mice from arthritis in the K/BxN-induced model and, in the T cell-mediated experimental autoimmune encephalomyelitis (EAE) mouse model, suppress disease by specifically activating regulatory T cells (Treg cells). Protection by these antiinflammatory Fcs in both antibody- and T cell-mediated autoimmune diseases required type II FcRs and the induction of IL-33. These results further clarify the mechanism of action of IVIG in both antibody- and T cell-mediated inflammatory diseases and demonstrate that Fc variants that mimic the structural alterations induced by sialylation, such as F241A, can be promising therapeutic candidates for the treatment of various autoimmune disorders.

IgG Fc sialylation | conformational change | antiinflammatory | Treg cells

Intravenous immunoglobulin (IVIG), although initially developed as an Ig replacement therapy in patients with hypogammaglobulinemia (1), has gained widespread use for its immunomodulatory activities. It is an approved therapeutic for the treatment of autoimmune disorders such as immunotrombocytopenia (ITP), chronic inflammatory demyelinating polyneuropathy, Kawasaki’s disease, and Guillain-Barre syndrome (2, 3), and is used in a growing number of autoimmune and inflammatory disorders. Its antiinflammatory activity has been shown to result from the presence of a specific glycans, the α2,6-sialylated, complex biantennary structure present on the C2 domain of the fragment crystallizable domain (Fc) and found in a small proportion of heterogeneous antibody preparations in IVIG (4). Sialylation of the Fc glycan on the C2 domain results in increased conformational flexibility of the C2 domain with corresponding modulation of Fc receptor (FcR) binding specificity from type I to type II receptors such as SIGN-R1, CD23, or human DC-SIGN. Studies in mouse models of serum-induced arthritis (11), while reducing their binding affinity to type I FcRs (9–11). Studies in mouse models of serum-induced arthritis, antibody-dependent ITP, nephrotic nephritis, and autoimmune blistering diseases confirmed the antiinflammatory activity of the sialylated Fc, whether from IVIG or generated from recombinantly expressed IgG1 (5, 9, 12, 13). Moreover, increasing the percentage of sialylated Fc fragments either in IVIG or recombinant expressed IgG1 resulted in an enhanced therapeutic potency of these preparations (6, 9, 12, 14). Elucidation of the mechanism by which sialylated IgG Fc (sFc) induces an antiinflammatory response was first reported in murine models of arthritis, demonstrating that selective binding of sialylated Fc to type II FcRs resulted in the production of interleukin (IL) 33 by regulatory macrophages, which in turn stimulated IL-4 secretion from basophils. IL-4 induced the up-regulation of the inhibitory receptor FcγRIIB on effector macrophages, thereby increasing the activation threshold of these cells and suppressing inflammation (15, 16). Subsequent studies have confirmed that IVIG treatment of human populations resulted in both increased serum IL-33 levels and FcγRIIB expression on lymphoid and myeloid cells, consistent with murine data (17–19).

Crystallographic and biophysical studies on sialylated and asialylated IgG Fc fragments have provided insights into the structural basis for the antiinflammatory activity of sialylated Fc. Sialylation of the complex, biantennary glycan of the IgG Fc results in increased conformational flexibility of the C2 domain (20), thereby sampling the closed conformations of the C2 domain required for type II FcR binding (11). In contrast, asialylated Fc structures uniformly result in open Fc conformations, consistent with their binding specificity for type I FcRs (21). Glycan interactions with amino acid residues of the C2 domain are disrupted upon sialylation, providing a basis for the observed conformational changes seen in the protein structure and consistent with a model proposed for the binding specificity of sialylated Fc for type II FcRs (11).

Based on these observations, we generated a series of Fc variants targeting the amino acids of the C2 domain that interact with the glycan, with the goal of determining their impact on type II FcR binding and the resulting antiinflammatory activity. Both gain- and loss-of-function mutants were examined in this study. The identification of a gain-of-function variant, which could mimic the conformational state induced by sialylation, without requiring this specific carbohydrate

Significance

IgG molecules are capable of inducing pro- and antiinflammatory responses dependent on their fragment crystallizable domain (Fc) glycan composition. Antiinflammatory responses are specifically triggered upon Fc sialylation, which decreases the binding affinity for type I Fc receptors but enhances binding to type II Fc receptors such as SIGN-R1, CD23, or human DC-SIGN. Structural analyses revealed that sialylation induces conformational changes in the Fc portion, which is a prerequisite for the selective binding to type II Fc receptors. Here we generated an Fc variant, F241A, that mimics the conformational state of sialylated Fc, F241A, even when nonsialylated, mediated protection from autoantibody- and T cell-mediated inflammation in a type II Fc receptor-dependent manner.

Author contributions: B.M.F., J.M., A.P., and J.V.R. designed research; B.M.F., J.M., A.P., and J.V.R. performed research; B.M.F., J.M., A.P., and J.V.R. analyzed data; and B.M.F. and J.V.R. wrote the paper.

Reviewers: D.M., Harvard Medical School; and F.N., University of Erlangen-Nuremberg. The authors declare no conflict of interest.

1Present address: Alecto Pharmaceuticals, San Francisco, CA 94107.

2To whom correspondence should be addressed. Email: ravetch@rockefeller.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1505292112/-/DCSupplemental.
modification, may potentially simplify the development of antiinflammatory IgG Fc for therapeutic use (20). We succeeded in identifying a mutation (F241A) predicted to increase mobility of the α1,3-arm, and which replicates the antiinflammatory activity of sialylated Fc even in the absence of sialylation. We have characterized this variant, in comparison with sialylated Fc, in both antibody and T-cell models of autoimmune inflammation.

Although the basis for IVIG protection in antibody-mediated models of inflammation has been extensively studied, as summarized above (9, 12, 13, 16), recent studies have demonstrated that IVIG can also protect in classical T cell-mediated autoimmune disorders, such as experimental autoimmune encephalomyelitis (EAE) (22), as well as in a model of airway hyperresponsiveness disorders, such as experimental autoimmune encephalomyelitis (EAE) (23, 24). This therapeutic effect of IVIG is proposed to result from the activation and expansion of regulatory T cells (Treg cells), thus (23, 24). This suggests that upon sialylation, the interaction between F241 and the α1,3-arm of the Fc glycan may be disrupted, which potentially contributes to the observed changes in antibody structure and function. Hence, to mimic this disruption in protein–glycan interaction, we introduced an alanine point mutation at residue F241 (F241A) and determined how this mutation altered the activity of sial and asial Fc. We produced α2,6-sialylated F241A Fc by expressing the recombinant protein in 293 cells stably overexpressing the glycosyltransferases ST6GalI and β4GalTI. For comparison, a fraction of this sial F241A Fc preparation was subsequently treated with neuraminidase to remove sialic acid, yielding asial F241A Fc. We confirmed the sialylation status of both F241A Fc preparations by lectin blotting (Fig. S1A). We next verified that sial F241A Fc retained DC-SIGN binding activity in an ELISA format, as demonstrated by increased receptor binding affinity relative to asial WT Fc (Fig. S2). However, neuraminidase treatment of F241A Fc did not abolish DC-SIGN binding, establishing that the F241A mutation conferred DC-SIGN binding activity independent of sialic acid. To determine whether the F241A mutation resulted in functional DC-SIGN binding and signaling, we investigated the ability of F241A and sFc to induce IL-33 expression in DC-SIGN–expressing bone marrow-derived macrophages (BMMΦs). Only sFc induces IL-33 expression in these cells, whereas both sialylated and asialylated F241A Fc induced IL-33 expression in BMMΦs in a DC-SIGN–dependent manner (Fig. 1B). Furthermore, human (h)DC-SIGN+ BMMΦs stimulated with asial F241A Fc, as well as sFc, suppressed footpad swelling when transferred to mice that were then challenged with

Results

F241A Mimics Sialylated IgG Fc and Protects from Autoantibody-Induced Inflammation.

The crystal structures of nonsialylated and sialylated IgG molecules show differences in the orientation of the heavy chains. Whereas nonsialylated IgG (G0F form) remains in an open conformation and provides a structure capable of interacting with type I Fc receptors, sialylated IgG (G2FS2 form) is more flexible, allowing alternate conformations (open and closed) (20) enabling it to bind to type II Fc receptors (11). As shown in Fig. 1A, the aromatic side chains of F241 in an asial Fc structure are stacked with respect to each other (Fig. 1A, Left). In this orientation, the phenylalanine side chain forms a hydrophobic interaction with sugar residues in the α1,3-arm of the Fc glycan. Surprisingly, the aromatic ring of F241 in the sial Fc structure exhibits a near-90° rotation relative to the aromatic ring of F241 in the asial Fc structure (Fig. 1A, Right). This suggests that upon sialylation, the interaction between F241 and the α1,3-arm of the Fc glycan may be disrupted, which potentially contributes to the observed changes in antibody structure and function. Hence, to mimic this disruption in protein–glycan interaction, we introduced an alanine point mutation at residue F241 (F241A) and determined how this mutation altered the activity of sial and asial Fc. We produced α2,6-sialylated F241A Fc by expressing the recombinant protein in 293 cells stably overexpressing the glycosyltransferases ST6GalI and β4GalTI. For comparison, a fraction of this sial F241A Fc preparation was subsequently treated with neuraminidase to remove sialic acid, yielding asial F241A Fc. We confirmed the sialylation status of both F241A Fc preparations by lectin blotting (Fig. S1A). We next verified that sial F241A Fc retained DC-SIGN binding activity in an ELISA format, as demonstrated by increased receptor binding affinity relative to asial WT Fc (Fig. S2). However, neuraminidase treatment of F241A Fc did not abolish DC-SIGN binding, establishing that the F241A mutation conferred DC-SIGN binding activity independent of sialic acid. To determine whether the F241A mutation resulted in functional DC-SIGN binding and signaling, we investigated the ability of F241A and sFc to induce IL-33 expression in DC-SIGN–expressing bone marrow-derived macrophages (BMMΦs). Only sFc induces IL-33 expression in these cells, whereas both sialylated and asialylated F241A Fc induced IL-33 expression in BMMΦs in a DC-SIGN–dependent manner (Fig. 1B). Furthermore, human (h)DC-SIGN+ BMMΦs stimulated with asial F241A Fc, as well as sFc, suppressed footpad swelling when transferred to mice that were then challenged with

---

**Fig. 1.** F241A is capable of suppressing serum-induced arthritis. (A) Schematic depiction of the interaction between mannose residues of the nonsialylated core glycan (Asialo-Fc) with the phenylalanine residue at position 241 of the Cγ2 domain. Upon sialylation (Sial-Fc) this interaction no longer occurs, resulting in a higher conformational flexibility of the Fc portion to switch between the so-called open and closed conformations. (B) hDC-SIGN+ bone marrow-derived macrophages were pulsed with sialylated (sFc) or nonsialylated (Fc) wild-type Fc or F241A Fc. Whole-cell extracts were used to analyze IL-33 production by Western blotting. Actin served as loading control. (C) BMMΦs from either SIGN-R1+ or hDC-SIGN+ mice were pulsed with nonsialylated wild-type Fc (asialo-Fc), sialylated wild-type Fc (sFc), or F241A. After extensive washes, the cells were adaptively transferred into C57BL/6 mice and then challenged with K/BxN serum. (D) hDC-SIGN+ BMMΦs were pulsed with either asialylated (asialo Fc) or sialylated (α2,6sFc) variants of wild-type Fc or F241A. The cells were adaptively transferred into C57BL/6 mice and then challenged with K/BxN serum. Means ± SEM are plotted; *P < 0.05; **P < 0.01 determined by Tukey’s post hoc test.
arthritogenic K/BxN serum. Protection was dependent on DC-SIGN expression (Fig. 1C). Furthermore, protection was only achieved with sialylated wild-type Fc, whereas the Fc mutant F241A was capable of protecting mice, even when nonsialylated (Fig. 1D). Thus, the F241A mutation recapitulates several Fc functions in assays developed to measure sial Fc activity.

To further define the activity of F241A as an antiinflammatory molecule, we treated C57BL/6 mice either with PBS, IL-4ic, or sialylated F241A (0.033 g/kg) and then challenged them with K/BxN sera. Serum IL-6 levels were significantly reduced in mice that received IL-4ic or F241A (Fig. 2A). Consistent with this observation, IL-4ic- and F241A-treated mice showed reduced clinical signs of arthritis (Fig. 2B), showing that F241A is sufficient to suppress inflammation comparable to IVIG and sFc (9, 12). To confirm that this suppression by F241A is type II FcR-dependent, we used SIGN-R1−/− or SIGN-R1+/+ hDC-SIGN+ recipients. Mice received either sialylated wild-type Fc or neuraminidase-treated nonsialylated F241A (Fig. S1A) (both 0.033 g/kg) and were challenged with K/BxN sera. Suppression of arthritic inflammation was achieved by both preparations; however, only mice that expressed human DC-SIGN (hDC-SIGN+) were protected (Fig. 2C), demonstrating that the presence of the type II Fc receptor SIGN-R1 or its human ortholog DC-SIGN, respectively, is required for the immunomodulatory effect induced by sialylated Fc and F241A.

Sialic acid can be linked to the penultimate galactose of the complex, biantennary Fc glycan in either α2,3-, α2,6-, or α2,8-conformations. We have previously reported that only the α2,6-linked glycoform of sialic acid is biologically active (12). Our previous modeling data on the structural analysis of different Fc sialoforms (11) predicted that the Glu318/Lys340 pocket at the Cα−Cγ1 interface was required for the biological activity of α2,6-sial Fc and could uniquely accommodate this glycoform, whereas the α2,3-linked sialic acid would be sterically inhibited from fitting into this pocket. To test this prediction, we introduced an E318N point mutation into IgG1 Fc and compared its properties, when α2,6-sialylated, to wild-type α2,6-sial Fc. Although comparable degrees of sialylation were achieved with the mutant compared with the wild type, only the wild-type sialylated Fc was capable of stimulating IL-33 expression in hDC-SIGN+ BMMΦs (Fig. S3A). Mice receiving BMMΦs stimulated with α2,6-sial wild-type Fc, but not α2,6-sial E318N Fc, exhibited reduced clinical signs of disease in the K/BxN serum transfer arthritis model (Fig. S3B), as well as lower levels of IL-6 (Fig. S3C). Together, these results define both F241A and E318A as residues that contribute to the antiinflammatory activity of α2,6-sial Fc.

**Sialylated Fc/F241A Activates Treg Cells.** Recent studies in patients and in animal models suggest that administration of IVIG can result in an expansion of Treg cells (22, 27), effectively dampening T cell-dependent autoimmune reactions by increasing the number and the suppressive capacity of Treg cells (28). To determine which component of an IVIG preparation may be responsible for this effect, we used IVIG (1 g/kg), F(ab')2 (0.66 g/kg), or Fc (0.33 g/kg) preparations of IVIG and administered them i.v. at equimolar concentrations into C57BL/6 wild-type mice. Four days post-injection, we analyzed the percentage of splenic CD4+CD25+Foxp3+ Treg cells by flow cytometry. In comparison with PBS-treated mice, administration of intact IVIG or its Fc fragments led to a twofold expansion of Treg cells and was abrogated by using IVIG F(ab')2 (Fig. 3A). We next determined the role of Fc sialylation in Treg-cell expansion in an ongoing inflammatory response. C57BL/6 mice were treated either with PBS, IVIG (1 g/kg), neuraminidase-treated nonsialylated IVIG (NA-IVIG) (1 g/kg), or F241A (0.033 g/kg) (Fig. S1B), challenged with K/BxN serum, and evaluated for disease progression and Treg-cell expansion. As observed previously (13, 29), clinical scores of arthritis showed that IVIG and F241A, but not nonsialylated IVIG, protected mice from arthritis (Fig. 3B). Treg-cell expansion was observed in IVIG- and F241A-treated mice that were subsequently challenged with K/BxN serum, but not in PBS- or asial IVIG-treated mice (Fig. 3C), suggesting that the Treg-cell subset becomes selectively expanded by sialylated Fc and F241A, respectively, in this model of arthritis.

*Fig. 2.* F241A induces antiinflammatory responses through engagement of type II Fc receptors. (A) C57BL/6 wild-type mice were treated with PBS, IL-4ic, or F241A (0.033 g/kg) and challenged 1 h later with K/BxN sera. Blood was collected from these mice 6 d posttreatment, and IL-6 levels in the sera were analyzed by ELISA. (B) Clinical scores of mice were monitored reflecting the severity of serum-induced arthritis. (C) SIGN-R1+/+ and hDC-SIGN+ mice were treated with sialylated wild-type Fc (sFc) or F241A (both 0.033 g/kg) and challenged 1 h later with K/BxN serum. Clinical examination of the mice was conducted daily until day 6 post K/BxN challenge, demonstrating the development and severity of arthritic inflammation. Means ± SEM are plotted; **P < 0.01; ***P < 0.001 determined by Tukey's post hoc test.
IVIG- or F241A-Activated Treg Cells Suppress Pathogenic CD4+ T-Cell Responses in Vivo. To evaluate whether Treg-cell expansion in response to IVIG, sFc, or F241A is able to suppress pathogenic CD4+ T-cell responses, we induced EAE in C57BL/6 wild-type mice by immunization with MOG35-55 peptide emulsified in complete Freund’s adjuvant (CFA). Starting 5 d postinduction, the mice were treated either with PBS, IVIG, or NA-IVIG every 5 d (at 1 g/kg). Clinical scores of EAE showed that mice that received IVIG had significantly reduced clinical scores compared with PBS-treated mice (Fig. 4A). However, when asial IVIG (NA-IVIG) (Fig. S1B) was administered, the protective effect was abolished. To determine the potential mechanistic basis for this effect, we characterized cells from draining lymph nodes at day 25 postinduction and analyzed the percentages of various T-cell subsets. All subpopulations of Treg cells from draining lymph nodes at day 25 postinduction and analyzed the potential mechanistic basis for this effect, we characterized cells were significantly elevated in mice that were given IVIG compared with PBS- or NA-IVIG-treated groups (Fig. 4C).

To assess whether the protection from EAE we observed in IVIG-treated animals was specifically mediated through activation and expansion of Treg cells, we tested the protective potential of F241A as a surrogate for IVIG in untreated and Treg cell-depleted mice. Treg-cell depletion was achieved by administration of an anti-CD25 antibody (PC61) 3 d before EAE induction and every 5 d thereafter. Mice treated with F241A (0.033 g/kg) displayed reduced disease severity compared with PBS-treated mice (Fig. 4D), demonstrating that F241A was effective at protecting animals from EAE at a 35-fold reduced dose compared with IVIG. However, in Treg-cell-depleted mice, this protective effect of F241A treatment was lost. FACs analysis of draining lymph nodes harvested at the conclusion of the study indicated that neither F241A nor PC61 treatment significantly affected CD4+ effector T cells (Fig. 4E), whereas Treg-cell levels were reduced by PC61 treatment (Fig. 4F). Depletion of Treg cells thus correlated with the loss of protection from EAE observed in F241A-treated animals. To distinguish between natural (nTreg) and inducible (iTreg) Treg cells, we analyzed the Treg cells in IVIG- and PBS-treated EAE mice for their expression of the nTreg-specific transcription factor Helios (30). The expansion of Treg cells in IVIG- and PBS-treated EAE mice for their expression of the nTreg-specific transcription factor Helios did not correlate with an increase in Helios expression (Fig. S4C), which indicates that IVIG (1 g/kg), which protected mice from EAE (Fig. S4 A and B), specifically induces CD4+CD25+Foxp3+Helios+ Treg cells.

Together, these results indicate that sialylated IVIG as well as F241A lead to the activation and expansion of Treg cells, resulting in the suppression of pathogenic CD4+ effector T-cell responses and clinical disease in EAE.

Type II Fc Receptors Are Required for sFc-Mediated Protection from EAE. The requirement for the type II Fc receptor SIGN-R1 or hDC-SIGN for sFc-induced suppression of inflammation has been extensively studied in the context of autoantibody-mediated diseases and for the stimulation of IL-33 production (29). We examined the requirement for the type II Fc receptor SIGN-R1 for sFc-mediated protection in EAE. EAE was induced in C57BL/6 wild-type or SIGN-R1−/− mice and then treated with IVIG (1 g/kg) or PBS as control. Whereas wild-type mice were protected from EAE by IVIG, this protective effect was significantly reduced in SIGN-R1 knockout mice (Fig. 5A). This is consistent with our observations that in the SIGN-R1−/− background, IVIG (1 g/kg) neither protects from K/BxN-induced arthritis (Fig. S5A) nor induces Treg-cell activation (Fig. S5B). By contrast, administration of exogenous IL-33 partially restored protection in SIGN-R1−/− mice from EAE (Fig. 5B). Similarly, transgene expression of hDC-SIGN partially complements the loss of SIGN-R1 (29) and results in reduced EAE clinical scores in both IVIG- (1 g/kg) and F241A- (0.033 g/kg) treated mice (Fig. 5 C and D).

IL-33 Is a Critical Mediator of sFc-Triggered Treg Cell Activation. We have previously reported that the up-regulation of FcγRIIB on
effectors and effector macrophages by sialylated Fc critically depends on production and secretion of IL-33 (29). Recent findings have indicated that IL-33 has a positive effect on Treg-cell stimulation and activation (31, 32) and thereby contributes to the suppression of inflammation in a mouse model of experimental colitis (33). To test the possibility that sFc-induced production of IL-33 may also contribute to Treg-cell stimulation, we confirmed that naive CD4+ T cells isolated from C57BL/6 wild-type mice, cultured for 3 d in the presence of anti-CD3 and anti-CD28 antibodies and TGF-β to specifically drive Treg-cell differentiation and then treated with IL-33, had a synergistic effect on Treg-cell differentiation as well as on Foxp3 expression (Fig. 6A), as was previously reported by Schiering and coworkers (33). Moreover, IL-33 induced up-regulation of the IL-33 receptor ST2 on Treg cells. Addition of IL-23 to the Treg-cell culture counteracted the effect of IL-33 (Fig. 6D), consistent with IL-23 being a negative regulator of ST2 (33, 34).

We next determined whether administration of IL-33 also affects Treg cells in vivo. IL-33 (0.5 μg) was given to C57BL/6 wild-type mice daily for 4 consecutive days. On day 5, spleens were analyzed for Treg-cell numbers. IL-33 administration resulted in a significant increase of Treg cells compared with PBS-treated control mice (Fig. 6A and B). hDC-SIGN+ BMMs were pulsed either with PBS, IVIG, or nonsialylated F241A, and IL-33 expression was measured by quantitative real-time PCR, showing that IVIG and F241A clearly induced IL-33 expression in a DC-SIGN-dependent manner (Fig. 6C). After treatment, BMMs were subsequently transferred into C57BL/6 wild-type mice. Five days post cell transfer, only mice that received IVIG- or F241A-pulsed hDC-SIGN+ BMMs had significantly higher levels of Treg cells (Fig. 6D and E). This phenotype correlated with enhanced expression of the IL-33 receptor ST2 on these cells (Fig. 6D). In addition, IL-33 treatment of EAE resulted in a significant amelioration of EAE symptoms, which correlated with an increase of Treg cells in draining lymph nodes (Fig. 6F and G).

Because FcγRIIB up-regulation on effector macrophages has been demonstrated to require the presence of basophils (29), we investigated whether basophils also play a role in the sFc-mediated Treg-cell activation pathway. Mice were treated with PBS or IVIG (1 g/kg) and challenged with K/BxN serum. Mice were also treated with an anti-FceRI antibody for depletion of basophils or with an isotype control (35). Whereas basophil depletion (Fig. 7A), as we have previously shown (29), prevented the therapeutic effect of IVIG in the K/BxN arthritis model (Fig. 7B), the ability of IVIG to expand Treg cells was not affected (Fig. 7C). This indicates that whereas IL-33 is required for Treg-cell activation, basophils, however, are not required.

sFc/F241A Activates Inducible Treg Cells via the IL-33/ST2 Axis. To further explore the mechanism of Treg-cell expansion and activation in response to sFc and type II FcεR engagement, we focused on the role of the IL-33 receptor ST2. As reported, IVIG- (1 g/kg) treated mice challenged with K/BxN serum in combination with an ST2 blocking antibody reduced the protective effect of IVIG in this serum transfer arthritis model (29) (Fig. 7A). FACS analysis of the Treg-cell numbers in these mice revealed that inhibition of IL-33 engagement by ST2 reduced the IVIG-induced expansion of Treg cells (Fig. 7B). Similarly, the therapeutic effect of F241A (0.033 g/kg) was significantly reduced by blocking the IL-33 receptor (Fig. 7C), with a concomitant reduction in Treg-cell expansion (Fig. 7D).

Finally, to determine the generality of our observations on the effect of sFc on T cell-mediated diseases, we used the experimental colitis mouse model and treated these mice weekly, starting 4 wk post T-cell transfer, with IVIG (1 g/kg) or PBS...
control until the end of the experiment. Body weight loss was used as a measure of disease severity, which showed that IVIG treatment mediated protection (Fig. 5 A, C, and D), and was again accompanied by a significant enrichment of Treg cells (Fig. S8B), whereas CD4+ effector T-cell levels were comparable in PBS- and IVIG-treated groups. Because only CD4+CD25+ T cells had been adoptively transferred to induce acute colitis, the IVIG-expanded Treg cells observed in these mice originated from peripheral CD4+ T cells and are thus consistent with iTreg cells.

Discussion
Antibodies mediate either proinflammatory or antiinflammatory effector functions through the differential engagement of type I or II Fc receptors, respectively. A complex, N-linked glycan attached to the C3′2 domain of IgG Fc regulates the interaction with these classes of FcRs by modulating the structure of the Fc to alternate between type I and type II binding conformations (8, 11, 20). The presence of an α2,6-linked sialic acid in this Fc-associated glycan results in reduced affinity for type I FcRs and enhanced binding to type II FcRs, such as DC-SIGN and CD23 (8, 11, 15). This switch in receptor specificity coincides with a switch in effector function in vivo, as sialylated IgG suppresses inflammation in mouse models of autoimmunity. Recent structural data support an earlier computational model that sialylation increases the conformational flexibility of the C3′2 domain, sampling conformations compatible with type II FcR binding (8, 20, 36).

Here we present functional data demonstrating that specific interactions between the Fc backbone and the Fc glycan influence the effector properties of sialylated IgG. We previously reported that the antiinflammatory activity of sial Fc depends strictly on the α2,6-linkage of sialic acid because only α2,6-sial Fc, but not α2,3-sial Fc, binds to DC-SIGN and suppresses autoimmune-induced arthritis inflammation (6). How can different sialic acid linkages on the Fc glycan influence Fc structure? We previously hypothesized that the proximity of the sialic acid sugar residue to the protein backbone may determine how sialic acid interacts with specific amino acid side chains on the Fc. Indeed, molecular modeling suggested that only α2,6-linked sialic acid could fit into a groove formed by Glu318 and Lys340 at the C3′2-C3′3 interface. To determine whether this groove plays a role in the antiinflammatory activity of α2,6-sial Fc, we characterized the immunosuppressive functions of sial Fc bearing an E318N point mutation. Interestingly, the E318N α2,6-sial Fc fails to initiate antiinflammatory pathways associated with WT α2,6-sial Fc, such as induction of IL-33 expression or protection from arthritis inflammation by adoptive transfer of stimulated DC-SIGN+ BMMs to K/BxN serum-challenged mice. Thus, as with the α2,3-linkage of sialic acid, we propose that the E318N mutation abolished the interaction between α2,6-linked sialic acid and the Fc backbone necessary for the Fc to adopt its closed, antiinflammatory state.

Fc structures typically resolve the α1,3-arms of the Fc glycan within the internal cavity formed by the C3′2 domains. By occupying this cavity, the α1,3-arms stabilize the C3′2 domains at a distance apart in the open conformation to facilitate binding to type I FcRs. In order for our proposed model to be correct, the sialylated α1,3-arms have to move out of this cavity toward the C3′2-C3′3 interface so that the terminal sialic acid may contact the E318/3340 groove. Thus, by repositioning the sialylated α1,3-arms to the C3′2-C3′3 interface, the C3′2 domains may draw closer together to fill the now unoccupied cavity and form the closed conformation. Unlike the α1,6-arm of the Fc glycan, which forms multiple noncovalent interactions with the Fc backbone, the α1,3-arm forms only one known contact in the absence of sialylation—the aromatic side chain of F241. However, in the crystal structure of sial Fc, the only amino acid side chain that contacts the Fc glycan to show a significant change in orientation is the ring structure of F241. We predict that the observed 90° rotation of F241 abrogates the hydrophobic stacking interaction it normally forms with the carbohydrate. We believe this to be structurally important, because the disruption of this stabilizing interaction should impart greater degrees of freedom, or mobility, to the sialylated α1,3-arms of the Fc glycan. We propose that with this greater mobility, the sialylated α1,3-arms will sample the space...
outside of the internal cavity with greater frequency to encounter the E318/K340 pocket at the CH2-CH3 interface. Consistent with the crucial role of F241 in the structure of α2,6-sial Fc, we found that an F241A mutation that specifically disrupts this protein-sugar contact point recapitulated the antiinflammatory activity of sial Fc independent of sialylation. Both α2,6-sial and -asial F241A Fc bound to DC-SIGN, induced IL-33 expression, and transferred antiinflammatory activity with stimulated DC-SIGN+BMMΦs to K/BxN serum-challenged mice, recapitulating the antiinflammatory activity of IVIG and sialylated IgG (29). Recently, reports have been published that question the essential role of Fc sialylation for modulating immune responses (37–39). Our data, and that of several other groups, have confirmed the antiinflammatory role of sialylated Fc in multiple models of antibody-mediated inflammation (9, 12–14, 16, 40). These discrepancies are likely the result of nonlinear dosing of IVIG in selective models used in those studies and thus not reflective of the physiologically relevant conditions in which IVIG is used.

We have identified that sialylated Fc, as well as F241A, specifically stimulated Treg-cell expansion and was sufficient to suppress T cell-mediated immune responses in models of EAE and experimental colitis by selective engagement of the type II Fc receptor SIGN-R1 or its human ortholog DC-SIGN. Furthermore, we could identify IL-33 as a mediator of this pathway. IL-33, induced in response to type II FcR engagement by IVIG, sialylated Fc, or F241A, acts pleiotropically, as summarized in Fig. S9. It can mediate IL-4 secretion by basophils to polarize macrophages to an M2 phenotype and induce inhibitory FcγRIIB expression, a pathway that dominates in antibody-mediated autoimmune inflammation, or it can act directly on Treg cells to mediate their activation and expansion. We could demonstrate that Treg cells can become activated by treatment with sialylated Fc and subsequent signaling through the IL-33/ST2 axis. We cannot exclude the possibility that the IL-33-dependent Treg-cell activation is mainly mediated indirectly via dendritic cells, as previously described by Matta and coworkers (32). However, our data do not support a direct interaction of IVIG with any T-cell subset, as has been proposed (22), nor could we observe any evidence in support of IVIG providing "Tregitopes" (41–44).

Previous studies have established the connection between IL-33 and an amelioration of T cell-mediated inflammation in different mouse models that were always accompanied by an enrichment of Treg cells (31, 45–48). Our studies demonstrate that IVIG, through the presence of sialylated Fc interacting with type II FcRs, provides a source of IL-33 that can induce Treg-cell activation and expansion. Consistent with these observations, serum levels of
IL-33 have been shown to be elevated upon IVIG administration in human autoimmune patients (19), thus making it a potent inducer of various antiinflammatory responses. When antibodies were used to block ST2 that prevented IL-33 signaling, we could observe that this treatment significantly compromised the protective effect of IVIG/F241A in both a serum transfer arthritis model as well as in an EAE model.

It is becoming increasingly clear that far from being a “constant” domain, the Fc region of antibodies exhibits heterogeneous structures and functions. This current study advances the view that the conformational diversity of the Fc fragment serves as a general strategy for antibodies to shift receptor specificity to effect different immunological outcomes. IgG Fc dynamics are fine-tuned by protein–glycan interactions, which are, in turn, regulated by the sugar composition of the Fc glycan. We find that a model of increased Fc glycan mobility accounts for the biophysical and functional properties associated with antiinflammatory activity of sialylated IgG. Based on these structural and mechanistic observations, we have developed a surrogate for sialylated IgG, F241A, which offers the benefit of greater potency and uniformity than IVIG and is a promising candidate for clinical development for both autoantibody- and T cell–mediated inflammatory diseases.

**Materials and Methods**

**Mice.** Six- to 10-wk-old sex- and age-matched C57BL/6, SIGN-R1−/−, and SIGN-R1+/−hDC-SIGN mice were used for all experiments in compliance with federal laws and institutional guidelines approved by The Rockefeller University. SIGN-R1−/− mice were bred to CD11c−DC-SIGN−/− littermates to generate SIGN−/− mice. K/RN T-cell receptor transgenic mice were on a C57BL/6 background and bred to nonobese diabetic (NOD) mice to create K/BxN mice. Six- to 10-wk-old sex- and age-matched C57BL/6, SIGN-R1−/−, and SIGN-R1+/−hDC-SIGN mice were used for all experiments in compliance with federal laws and institutional guidelines approved by The Rockefeller University. SIGN-R1−/− mice were bred to CD11c−DC-SIGN−/− littermates to generate SIGN-R1−/−hDC-SIGN−/− mice. KRN T-cell receptor transgenic mice were on a C57BL/6 background and bred to nonobese diabetic (NOD) mice to create K/BxN mice.

**Flow Cytometry.** To analyze lymphocytes and bone marrow cells, single-cell suspensions were prepared from spleens, lymph nodes, and bone marrow. After red blood cell lysis, cells were stained with the respective antibodies and analyzed using a FACSCalibur (BD Biosciences). The antibodies used for murine cell stainings were anti-CD4 (GK1.5), anti-Foxp3 (FJK-16s), and anti-CD11b (M1/70), and anti-F4/80 (BM8) from BioXcell; anti-CD25 (PC61), anti-CD28 (37.51), anti-CD69 (H1.2F3), anti-CD3 (145-2C11), anti-CD20 (2H7), anti-CD8 (53-6.7), anti-CD95 (Jo2), and anti-Helios (22F6) from Bio X Cell; 3 d before EAE induction as well as 1 d after each IVIG/F241A injection until the end of the experiment.

**Cytokine treatment.** Mice received a single i.v. injection of 2.5 μg IL-4ic (PeproTech) or 0.5 μg IL-33 i.p. on 4 consecutive days or every 2 d in EAE experiments. IL-6 serum levels were measured by an in vivo cytokine capture assay as described (51). IL-33 in cell-culture supernatants was detected and measured by ELISA as suggested by the manufacturer (eBioscience).

**Differentiation of Bone Marrow-Derived Macrophages and Transfers.** Bone marrow cells were isolated from femurs and tibias, and cultured in 10-cm plates in DMEM supplemented with 20% (vol/vol) FBS, 2% (vol/vol) penicillin/streptomycin...